@TheGoalIsToStayOutOfTheHole
The research already done on Lupron (though more needs to be done) doesn't look that good.
I'd certainly suggest calling it "not dangerous" was naive at best.
Based on the data available now, I can't understand why it's being given to children as adverse effects on bone density in adults are known.
Most info comes from children who were treated for precocious puberty. This treatment was then co-opted by trans "supportive" medical professionals but there is doubt as to whether it should even have been licensed for precocious puberty. It's also worth noting the drugs label denotes usages before the ages of 8/9 years for female/male children respectively. The drug is routinely prescribed for children significantly older.
https://www.statnews.com/2017/02/02/lupron-puberty-children-health-problems/
AbbVie Inc., the company that now makes the drug, said Lupron safety studies were submitted to the FDA before it approved the medication for Central Precocious Puberty in 1993. The drug’s label defines the condition as the onset of sexual characteristics before age 8 in girls and before 9 in boys.
“Uses beyond those contained in the approved label are considered unapproved uses,” company spokesman Morry Smulevitz said in an email.
Federal records show that the FDA official who led the drug approval process two decades ago was troubled by the two studies he reviewed. In a 1993 letter obtained under the Freedom of Information Act, former FDA medical officer Dr. Alexander Fleming wrote in a memo for the drug approval file that it was “regrettable” that the panel approved the drug after minimal study.